Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis

Autor: Kittipong Maneechotesuwan, Dave Singh, Leandro G. Fritscher, Nese Dursunoglu, Abhijith P.G., Abhay Phansalkar, Bhumika Aggarwal, Emilio Pizzichini, Justyna Chorazy, Heather Burnett

Publikováno v: Respiratory medicine. 203

This network meta-analysis (NMA) compared fixed-dose, twice daily fluticasone propionate/salmeterol (FP/Sal) vs. inhaled corticosteroid (ICS) and other ICS/long-acting beta-agonists (LABA) treatments, including when administered using maintenance and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb0b01b3c241895272b4145715d3c99f
https://pubmed.ncbi.nlm.nih.gov/36257125

Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis.

Autor: Maneechotesuwan K; Division of Respiratory Disease and Tuberculosis, Department of Medicine, Mahidol University, Bangkok, Thailand., Singh D; University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK., Fritscher LG; Faculty of Medicine, Pontific Catholic University (PUCRS), Porto Alegre, Brazil., Dursunoglu N; Department of Chest Diseases, Pamukkale University School of Medicine, Denizli, Turkey., P G A; GSK, Singapore, 139234, Singapore. Electronic address: abhijith.x.pg@gsk.com., Phansalkar A; GSK, Mumbai, India., Aggarwal B; GSK, Singapore, 139234, Singapore., Pizzichini E; GSK, Brentford, Middlesex, UK., Chorazy J; Evidera, Needham, MA, USA., Burnett H; Evidera, Needham, MA, USA.

Publikováno v: Respiratory medicine [Respir Med] 2022 Nov; Vol. 203, pp. 106993. Date of Electronic Publication: 2022 Sep 21.